Carnosine
Also known as: Beta-Alanyl-L-Histidine, L-Carnosine, Ignotine
Overview
Carnosine is an endogenous dipeptide (β-alanyl-L-histidine) found in high concentrations in skeletal muscle, cardiac muscle, and neuronal tissue. It is a multifunctional bioactive molecule with antioxidant, metal-chelating, anti-glycation, and pH-buffering properties. Muscle carnosine levels decline with age and are elevated by beta-alanine supplementation. In the context of aging, carnosine has attracted attention for its ability to prevent protein glycation, chelate redox-active metals (Cu²⁺, Zn²⁺), and extend cellular lifespan in culture studies. It has also been studied for cognitive protection and exercise performance.
Mechanism of Action
Carnosine acts through multiple complementary mechanisms: (1) Antioxidant — directly quenches reactive oxygen species and singlet oxygen; (2) Anti-glycation — reacts with reducing sugars and aldehyde carbonyl groups, preventing AGE (advanced glycation end-product) formation on long-lived proteins; (3) Metal chelation — forms stable complexes with Cu²⁺ and Zn²⁺, reducing metal-catalyzed oxidative damage; (4) pH buffering — histidine's imidazole group (pKa ~6.8) buffers intramuscular pH during high-intensity exercise, delaying fatigue; (5) Transglycation — can remove glycation adducts from already-glycated proteins.
Potential Benefits
- Anti-glycation protection of long-lived proteins
- Intramuscular pH buffering during high-intensity exercise
- Neuroprotection in models of Alzheimer's disease
- Antioxidant activity in ischemia/reperfusion models
- Potential lifespan extension (animal models)
- Metal chelation reducing oxidative damage
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 500 mg daily with breakfast |
| Intermediate | 1000 mg daily split AM/PM |
| Advanced | 1500-2000 mg daily split 2x (often with zinc) |
| Cycle Duration | Continuous supplementation |
Dipeptide (β-alanyl-L-histidine). Rapidly hydrolyzed by serum carnosinase — β-alanine is the practical precursor for muscle carnosine loading.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral (capsule/powder) Low (serum carnosinase hydrolysis) — but muscle uptake occurs via β-alanine
Standard supplement route. Consider β-alanine for performance ergogenic use.
Topical/ophthalmic (NAC + carnosine) Local
N-acetyl-carnosine eye drops marketed (controversially) for cataracts.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Carnosine:
Glycation Defense Stack
Anti-glycation and mitochondrial support — carnosine scavenges carbonyls, benfotiamine blocks AGE pathways, ALA supports redox balance.
Performance Stack
β-Alanine (carnosine precursor) 3.2-6.4 g daily + creatine 3-5 g daily for muscle buffering and phosphagen capacity.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store capsules/tablets at room temperature in a dry, dark place. Liquid formulations refrigerated. |
|---|
Oral peptide — no reconstitution required. Follow product label for storage specifics.
Need exact syringe measurements?
Amino Acid Sequence
β-Ala-His
Side Effects & Safety
- Generally well-tolerated
- Beta-alanine component: paresthesia (tingling) at high beta-alanine doses
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store at room temperature (15-25°C) in a dry, dark place. Keep tightly closed. Do not refrigerate capsules. |
Synergistic Compounds
The following compounds have been studied alongside Carnosine for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.